BIOFLOW-III Belgium Satellite Registry
CompletedNCT01831336
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
This registry is a clinical post-market evaluation of the Orsiro LESS in subjects requiring coronary revascularization with Drug Eluting Stents (DES).
Study details
- Official title
- BIOTRONIK - SaFety and Performance Registry for an All-comers Patient Population With the Limus Eluting Orsiro Stent System Within Daily Clinical Practice - III Belgium
- Sponsor
- Biotronik Belgium NV
- Start date
- 2013-02
- Primary completion
- 2016-06
- Sex
- All
- Age range
- from 18 Years
- Results posted
- No results posted in this snapshot
- Countries
- Belgium
- Total sites listed
- 8
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Symptomatic coronary artery disease * Subject has signed informed consent for data release * Subject is geographically stable and willing to participate at all follow-up assessments * Subject is ≥ 18 years Exclusion Criteria: * Subject did not sign informed consent for data release * Pregnancy * Known intolerance to aspirin, clopidogrel, ticlopidine, heparin or any other anticoagulation / antiplatelet therapy required for PCI, stainless steel, Sirolimus or contrast media * Planned surgery within 6 months of PCI unless dual antiplatelet therapy will be maintained * Currently participating in another study and primary endpoint is not reached yet.
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT01831336